SCHEMBL10459767

SCHEMBL10459767

O=C(O)c1ccc(-c2cccc(OCc3ccccc3)c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.79
NR4A2 P43354 3/20 0.74
SRD5A2 P31213 2/20 0.70
RXRA P19793 3/20 0.69
RXRB P28702 3/20 0.69
PTGES O14684 1/20 0.68
ALOX5 P09917 1/20 0.68
LTC4S Q16873 1/20 0.68
TSHR P16473 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
NR4A1 P22736 1/20 0.67
NR4A3 Q92570 1/20 0.67
NR1H4 Q96RI1 1/20 0.64
RXRG P48443 1/20 0.63
SMPD1 P17405 1/20 0.61
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
HDAC4 P56524 1/20 0.59
MAP4K4 O95819 1/20 0.59
PLA2G4B P0C869 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18625354 0.91 NR4A2 (0.77) MRGPRX4NR4A2SRD5A2RXRARXRB
SCHEMBL27734092 0.90 MRGPRX4 (0.73) MRGPRX4NR4A2SRD5A2RXRARXRB
SCHEMBL3565625 0.88 MRGPRX4 (1.00) MRGPRX4NR4A2SMN1; SMN2NR1H4
SCHEMBL16321477 0.88 MEN1 (0.73) MRGPRX4NR4A2SRD5A2RXRARXRB
SCHEMBL3678773 0.86 MRGPRX4 (0.64) MRGPRX4NR4A2SRD5A2RXRARXRB
SCHEMBL5944125 0.86 SMPD1 (0.79) MRGPRX4NR4A2NR1H4SMPD1HDAC4
SCHEMBL4949143 0.86 NR4A2 (0.90) NR4A2SRD5A2RXRARXRBPTGES
SCHEMBL2137838 0.86 MRGPRX4 (0.69) MRGPRX4NR4A2ALOX5HDAC4MAOB
SCHEMBL7477872 0.85 MRGPRX4 (0.74) MRGPRX4NR4A2SRD5A2SMN1; SMN2NR4A1
SCHEMBL1123461 0.85 NR4A2 (0.81) MRGPRX4NR4A2SRD5A2RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 US disclosed
EP-3694840-B1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 EP disclosed
US-20200299277-A1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-09-24 US disclosed
US-4916145-A PLATELET ACTIVATING FACTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 1990-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG MRGPRX4 85/4885NR4A2 4745/4885SRD5A2 4796/4885
US-20200299277-A1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS MAGI3, PYM1, MAG MRGPRX4 85/4885NR4A2 4745/4885SRD5A2 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.